Navigation Links
Lipitor Lawsuit News: Judicial Panel Denies Consolidation of Federal Cases, Rottenstein Law Group LLP Reports
Date:9/11/2013

(PRWEB) September 11, 2013

A federal panel of judges, after three months of deliberation, denied a motion for consolidation of Lipitor-induced Type 2 diabetes cases, according to an Aug. 8 panel order.* The Rottenstein Law Group LLP, a Lipitor law firm, offers an explanation of what the decision means for those looking to file Lipitor lawsuits.

The U.S. Judicial Panel on Multidistrict Litigation oversees consolidations of federal lawsuits. In its order, the JPML wrote that, “in particular, almost half of the actions currently comprising this litigation are pending in a single district—the District of South Carolina, and many of the actions involve common plaintiffs’ counsel. The South Carolina actions already are proceeding in a coordinated fashion before one judge.”

In the order, the JPML also indicated that Pfizer was willing to coordinate with the plaintiffs with regard to the consolidation of pretrial proceedings such as common discovery, which is the primary purpose of a multidistrict litigation. Therefore, the JPML denied the motion to create an MDL, according to the order.

“The decision of the Panel isn’t controversial, and it certainly should not be discouraging to any potential plaintiff,” said Rochelle Rottenstein, principal of the Rottenstein Law Group LLP. “The Panel saw that there are currently a small number of Lipitor suits, most of which are already in the same court. Anyone who has taken Lipitor and suffered adverse side effects has the same opportunity to sue for compensation as always. The Panel decision doesn’t change that at all.”

The Lipitor lawsuits focus on the claim, supported by at least two research studies, that links the use of the drug and a risk of Type 2 diabetes. A 2011 American College of Cardiology study established a connection between the statin and the diabetes risk, and a January 2012 JAMA: Internal Medicine study highlighted the risk in women.**

The Rottenstein Law Group LLP encourages those who have taken Lipitor to download a free informational brochure that discusses Lipitor side effects and how to file a Lipitor lawsuit.

*In Re: Lipitor (Atorvastatin Calcium) Marketing, Sales Practices and Products Liability Litigation, MDL-2459, JPML. http://www.jpml.uscourts.gov/sites/jpml/files/MDL-2459-Denied_Transfer-07-13.pdf

**archinte.jamanetwork.com/article.aspx?articleid=1108676

About THE ROTTENSTEIN LAW GROUP LLP
The Rottenstein Law Group LLP is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and drugs. (Attorney advertising. Prior results do not guarantee a similar outcome.)

Contact:
The Rottenstein Law Group LLP
Rochelle Rottenstein, Esq.
321 W. 44th Street
# 804
New York NY 10036
(212) 933-9500 (office phone)
(212) 933-9980 (facsimile)
rochelle (at) rotlaw (dot) com
                            ###

Read the full story at http://www.prweb.com/releases/lipitor-lawsuits/diabetes/prweb11110224.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. Lipitor Lawsuit Website Launched by Bernstein Liebhard LLP to Provide Information to the Public Regarding Lipitor Side Effects, Ongoing Litigation
2. National Law Firm Baron and Budd Helping Women with Alleged Injuries from Lipitor Use Understand the Lipitor Lawsuit
3. National Law Firm Baron and Budd Responds to Disproportionate Harm Brought to Women Using Lipitor, According to Study
4. Lipitor News: Rottenstein Law Group LLP Comments on Boomers’ Favorite Drug
5. Lipitor Lawsuit News: Rottenstein Law Group LLP Responds to Reports of Lipitor Giveaway
6. Lipitor Lawsuit News: US Spending on Drugs Fell For First Time in 2012, Notes Rottenstein Law Group LLP
7. Lipitor Lawsuit News: Rottenstein Law Group Comments on FDA Approval of New Drug With Lipitor Compound
8. Lipitor Diabetes Lawsuit Filed by South Carolina Woman Who Developed Type 2 Diabetes Allegedly Due to Lipitor Use, Alonso Krangle Investigating
9. DrugNews: Latest Info Shows Rise in NuvaRing Lawsuits Alleging Blood Clots
10. Da Vinci Robot Lawsuit Lawyers at Wright & Schulte LLC Disturbed by New Study Examining Risks and Benefits of Robotic Surgery Hysterectomy
11. Actos Lawsuit Filed By Wright & Schulte on Behalf of Ohio Man Alleges Extended Use of Type-2 Diabetes Drug Caused Him to Develop Bladder Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... February 24, 2017 , ... Indiana Fiber Network (IFN) ... company later this year. Dyer started as the Chairman of the Management Committee ... establishment of the corporation including the recruitment of investor/owners and development of the business ...
(Date:2/23/2017)... TX (PRWEB) , ... February 23, 2017 , ... ... announced an official 2017 partnership with The Jensie Gran Fondo of Marin. For ... and UVB rays with Thinksport’s broad-spectrum, mineral-based sunscreen. , “We are thrilled to ...
(Date:2/23/2017)... , ... February 23, 2017 , ... The American Cleft ... ACPA’s 74th Annual Meeting. KLS is a longtime supporter of the event. , ... exhibitor and Platinum Sponsor," said Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has ...
(Date:2/23/2017)... ... February 23, 2017 , ... On April 13, ... symposium on “Doping in Sport: How the Culture Might Change,” in ... LLP. The symposium will be held at Pepperdine University in Malibu, California. , ...
(Date:2/23/2017)... ... February 23, 2017 , ... Healthcare Research & Analytics® (HRA®) ... fight against cancer, has produced a seminal study that asked cancer survivors and ... findings in a webinar, Defining Compassionate Care Through the Voices of Patients and ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Research and Markets has announced the addition of the ... to their offering. ... The latest research Fibromyalgia Drugs Price Analysis and Strategies - ... market. The research answers the following questions: ... their clinical attributes? How are they positioned in the Global Fibromyalgia ...
(Date:2/23/2017)... Regulus Therapeutics Inc . (Nasdaq: RGLS), ... innovative medicines targeting microRNAs, today announced it will release ... Thursday, March 2, 2017 after the market closes. ... on March 2, 2017 at 5:00 p.m. Eastern Time ... results and provide a general business update.  A live ...
(Date:2/23/2017)... 23, 2017 According to a ... (X-ray Imaging Digital, Analog), MRI (Closed, Open), Ultrasound, CT, ... Oncology), End User (Hospitals, Imaging Centers) - Global Forecast ... global market over the forecast period of 2016 to ... Billion by 2021, at a CAGR of 6.6% from ...
Breaking Medicine Technology: